Merck & Co. (MRK) — indication breadth, read against the 10-Q

Merck & Co.reason 01 of 4not in the tablederived 2026-09-11accession 0000310158-26-000212

Keytruda's indication breadth across 45+ approved uses creates multiple demand vectors that compound as earlier-stage indications gain utilization, while the 2.5% royalty expiration at year-end 2026 will structurally improve margins on the franchise going forward.

the thesis · admitted · the reason above is the thesis, not printed twice

the finding

The disclosure now explicitly states Keytruda is approved in over 45 indications in the U.S. including 19 tumor types and 2 tumor-agnostic indications, directly relevant to the indication breadth component of the reason.

The report says this changed. It does not say whether that is good or bad, so neither do we.

before · MD&A · 2026-03-31 → 2026-06-30

“Keytruda Qlex , which was initially approved by the FDA in September 2025, is approved in the U.S. in solid tumor indications approved for Keytruda .”